Product Description: Purvalanol A is a potent CDK inhibitor, which inhibits cdc2-cyclin B, cdk2-cyclin A, cdk2-cyclin E, cdk4-cyclin D1, and cdk5-p35 with IC50s of 4, 70, 35, 850, 75 nM, resepctively.
Applications: Cancer-Kinase/protease
Formula: C19H25ClN6O
References: [1]Gray NS, et al. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science. 1998 Jul 24;281(5376):533-8./[2]Bain J, et al. The specificities of protein kinase inhibitors: an update. Biochem J. 2003 Apr 1;371(Pt 1):199-204./[3]Villerbu N, et al. Cellular effects of purvalanol A: a specific inhibitor of cyclin-dependent kinase activities. Int J Cancer. 2002 Feb 20;97(6):761-9.
CAS Number: 212844-53-6
Molecular Weight: 388.89
Compound Purity: 98.30
Research Area: Cancer
Solubility: DMSO : ≥ 50 mg/mL/Ethanol : 10 mg/mL (ultrasonic)
Target: Apoptosis;Autophagy;CDK
Deutsch
English
